文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

亚甲蓝在心源性休克与心脏骤停中的应用:系统评价

Methylene blue in cardiogenic shock and cardiac arrest: A systematic review.
PubMed 文献 · Shock · 2025-09-09
一句话结论亚甲蓝在心源性休克与心脏骤停中的人类数据缺乏,部分动物模型显示潜在治疗信号,需前瞻性研究验证。

该系统评价检索MEDLINE、EMBASE、CENTRAL、Scopus和Web of Science(2025年3月),纳入6项临床前随机动物研究和1项回顾性人类队列研究。早期猪心室颤动模型在CPR期间持续输注亚甲蓝显示改善生存、血流动力学和神经结局;而近期采用梗死诱导模型、仅推注给药的严谨研究显示获益极小或无获益。唯一的人类研究缺乏对照组,心源性休克特异性结局数据有限。结论认为亚甲蓝在该人群尤其人类中数据缺乏,部分动物模型存在潜在治疗信号,需前瞻性研究验证。

要点

  • 系统评价仅纳入7项研究:6项临床前随机动物研究和1项回顾性人类队列研究,人类证据极为有限。
  • 早期猪电诱导心室颤动模型在CPR期间持续输注亚甲蓝显示改善生存、血流动力学和神经结局。
  • 近期梗死诱导模型仅推注给药的研究显示亚甲蓝获益极小或无获益。
  • 唯一人类研究缺乏对照组,心源性休克特异性结局数据有限,无法据此推荐临床使用。
  • 作者认为需在临床相关心脏损伤模型中进行前瞻性研究以确定亚甲蓝能否改善该高危人群结局。

适用人群与场景

  • 成人或动物模型的心源性休克或心脏骤停患者(系统评价纳入标准)。

研究设计与关键结果

  • 系统评价检索676条记录,最终纳入7项研究:6项临床前随机动物研究和1项回顾性人类队列研究。
  • 早期猪电诱导心室颤动模型在CPR期间持续输注亚甲蓝显示改善生存、血流动力学和神经结局。
  • 近期采用梗死诱导模型、仅推注给药的研究显示亚甲蓝获益极小或无获益。
  • 唯一人类研究缺乏对照组,提供的心源性休克特异性结局数据有限。

证据类型、等级与局限

  • 证据类型:系统评价,纳入6项临床前随机动物研究和1项回顾性人类队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 现有证据不足以支持在成人心脏骤停或心源性休克中常规使用亚甲蓝。
  • 作者认为需在临床相关心脏损伤模型中进行前瞻性研究以确定亚甲蓝能否改善该高危人群结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Cardiogenic shock and cardiac arrest are associated with high risk of mortality despite advances in resuscitation techniques and supportive care. A growing body of evidence implicates a systemic inflammatory response syndrome (SIRS) in the pathogenesis of post-arrest vasoplegia and end-organ injury. Methylene blue (MB), a nitric oxide pathway inhibitor, has shown efficacy in vasoplegic and septic shock, yet its role in cardiogenic shock or cardiac arrest is not well established.

METHODS: We conducted a systematic review of peer-reviewed studies examining methylene blue in cardiogenic shock or cardiac arrest. Electronic databases MEDLINE, EMBASE, CENTRAL, Scopus, and Web of Science were searched in March 2025. Preclinical randomised trials and clinical studies in adult humans or animal models were included.

RESULTS: Out of 676 screened records, seven studies met inclusion criteria: six preclinical randomised animal studies and one retrospective human cohort study. Early porcine studies using electrically induced ventricular fibrillation and continuous MB infusion during CPR demonstrated improved survival, haemodynamic profile, and neurologic outcomes. In contrast, more recent, well conducted bolus-only studies using infarct-induced models reported minimal or no benefit associated with MB administration. The single human study lacked a comparator group and provided limited cardiogenic shock-specific outcome data.

CONCLUSIONS: This systematic review highlights the lack of data available for MB in cardiogenic shock and cardiac arrest, especially in humans. There was a potential therapeutic signal for methylene blue in some animal models of cardiogenic shock and cardiac arrest. Prospective studies with clinically relevant models of cardiac injury are warranted to determine whether MB can improve outcomes in this high-risk population.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Batchelor RJ, Watkins M, Bloom JE, et al. Methylene blue in cardiogenic shock and cardiac arrest: A systematic review. Shock. 2025. PMID: 40961396. doi:10.1097/SHK.0000000000002700

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。